ReviewScientifica2012
Diabetes technology: markers, monitoring, assessment, and control of blood glucose fluctuations in diabetes.
Review in Scientifica, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02403427 (The Voice Decision Support Expert System in Basal-bolus Insulin Therapy of Diabetes Patients.), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Voice Decision Support Expert System in Basal-bolus Insulin Therapy of Diabetes Patients.
Who cites it
10 citing papers in PubMed, 30 citations in OpenAlex.
- Glycemic Variability and Gut Microbiota Metabolic Patterns: A Novel Perspective on Diabetic Complications.Food science & nutrition · 2025Review
- Design of dual hormone blood glucose therapy and comparison with single hormone using MPC algorithm.IET systems biology · 2020Article
- A Flexible Interdigital Electrode Used in Skin Penetration Promotion and Evaluation with Electroporation and Reverse Iontophoresis Synergistically.Sensors (Basel, Switzerland) · 2018Article
- Measures of Risk and Glucose Variability in Adults Versus Youths.Diabetes technology & therapeutics · 2015Article
- The Evolving Role of Short-Term Professional Continuous Glucose Monitoring on Glycemic Control and Hypoglycemia Among Saudi Patients with Type 1 Diabetes: A Prospective Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2015Article
- Q-Score: development of a new metric for continuous glucose monitoring that enables stratification of antihyperglycaemic therapies.BMC endocrine disorders · 2015Article
- Physical activity and type 1 diabetes: time for a rewire?Journal of diabetes science and technology · 2015Review
- DiAs user interface: a patient-centric interface for mobile artificial pancreas systems.Journal of diabetes science and technology · 2013Article
- Evaluation of stream mining classifiers for real-time clinical decision support system: a case study of blood glucose prediction in diabetes therapy.BioMed research international · 2013Article
- RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020.Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
People with diabetes face a life-long optimization problem: to maintain strict glycemic control without increasing their risk for hypoglycemia. Since the discovery of insulin in 1921, the external regulation of diabetes by engineering means has became a hallmark of this optimization. Diabetes technology has progressed remarkably over the past 50 years-a progress that includes the development of markers for diabetes control, sophisticated monitoring techniques, mathematical models, assessment procedures, and control algorithms. Continuous glucose monitoring (CGM) was introduced in 1999 and has evolved from means for retroactive review of blood glucose profiles to versatile reliable devices, which monitor the course of glucose fluctuations in real time and provide interactive feedback to the patient. Technology integrating CGM with insulin pumps is now available, opening the field for automated closed-loop control, known as the artificial pancreas. Following a number of in-clinic trials, the quest for a wearable ambulatory artificial pancreas is under way, with a first prototype tested in outpatient setting during the past year. This paper discusses key milestones of diabetes technology development, focusing on the progress in the past 10 years and on the artificial pancreas-still not a cure, but arguably the most promising treatment of diabetes to date.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.